Adicet Bio, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Adicet Bio released a September 2026 investor presentation outlining clinical progress on prula-cel (allogeneic gamma-delta CAR-T for autoimmune diseases) with data through August 2025 from 7 patients (5 lupus nephritis, 2 SLE) showing efficacy comparable to autologous CAR-T with favorable safety (no grade ≥2 CRS, no ICANS). ADI-212 (gene-edited PSMA-targeted CAR-T for metastatic castrate-resistant prostate cancer) received IND clearance and plans first-patient dosing in 4Q2026 with clinical data expected 1H2027. The company outlined a diversified in vivo CAR-T pipeline for multiple myeloma, NHL, and solid tumors, with first candidate entering clinic in 2H2027.
Why this rating
Early-stage clinical data (n=7, 2–9 month follow-up) from prula-cel is positive for efficacy/safety but very preliminary; IND clearance for ADI-212 is routine regulatory milestone. Pipeline is pre-clinical/early clinical. No financial deals, financing, leadership changes, or material business developments disclosed. For a $50.5M market-cap biotech, these are typical development milestones, not trajectory-altering. Execution and pivotal trial success remain highly uncertain.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.